UNIVERSITY CLINICAL CENTER PROF. K. GIBIŃSKI MEDICAL UNIVERSITY OF SILESIA IN KATOWICE has floated a tender for Delivery of Medicinal Products. The project location is Poland and the tender is closing on 25 Mar 2024. The tender notice number is 110414-2024, while the TOT Ref Number is 97372838.
Bidders can have further information about the Tender and can request the complete Tender document by Registering on the site.
Procurement Summary
Country : Poland
Summary : Delivery of Medicinal Products
Deadline : 25 Mar 2024
Other Information
Notice Type : Tender
TOT Ref.No.: 97372838
Document Ref. No. : 110414-2024
Competition : ICB
Financier : Self Financed
Purchaser Ownership : Public
Tender Value : Refer Document
Purchaser's Detail
Purchaser : UNIVERSITY CLINICAL CENTER PROF. K. GIBIŃSKI MEDICAL UNIVERSITY OF SILESIA IN KATOWICE Address: ul. Ceglana 35
Town: Katowice
NUTS-Code: PL22A
Postal Code: 40-514
Phone: 32 358 1442 Poland Email :acholuj@uck.katowice.pl URL :https://www.uck.katowice.pl/
Tender Details
Delivery of medicinal products divided into 33 parts
Part 1 - Formulated substances
Part 1 - Formulated substances - specification and quantitative assortment specified in Annex 4.1 SWZ
Part 2 - Immunoglobulin 1
Part 2 - Immunoglobulin I - specification and quantitative assortment specifiedincluded in Annex 4.2 SWZ
Part 3 - Trabectedin
Part 3 - Trabectedin - specification and quantitative specification are specified in Annex 4.3 SWZ
Part 4 - Bevacizumab
Part 4 - Bevacizumab - specification and quantitative specification are specified in Annex 4.4 SWZ
Part 5 - Lanreotide
Part 5 - Lanreotide - product and quantity specification is specified in Annex 4.5 SWZ
Part 6 - Aflibercept
Part 6 - Aflibercept - product and quantity specification is specified in Annex 4.6 SWZ
Part 7 - Dexamethasonum
Part 7 - Dexamethasonum - product and quantity specification okare specified in Annex 4.7 SWZ
Part 8 - Pasireotide
Part 8 - Pasireotide - specification and quantitative specification are specified in Annex 4.8 SWZ
Part 9 - Miscellaneous drugs
Part 9 - Miscellaneous drugs - specification and quantitative assortment are specified in Annex 4.9 SWZ
Part 10 - Immunoglobulinm II
Part 10 - Immunoglobulinum II - product and quantity specification specified in Annex 4.10 SWZ
Part 11 - Propofolum
Part 11 - Propofolum - product and quantitative specification specified in Annex 4.11 SWZ